Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Participants receiving 8 mg weekly achieved around 17% weight loss over 36 weeks, with weight continuing to fall when follow-up was extended
Participants in clinical trials lost significant weight with both forms
.webp)
This can lead to denial at renewal because the insurer cannot confirm ongoing clinical effectiveness
For healthcare professionals, this approval provides a new treatment option to help us address cardiovascular residual risk that remains for patients on current standard of care. Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight, said John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research
)
